Introduction
Down's syndrome is the most common form of chromosomal trisomy in humans with an incidence of one in 733 live births [1] . Triplication of human chromosome 21 (HSA21) leads to a number of characteristic phenotypes, including musculoskeletal defects, mental retardation, heart defects, and early-onset of Alzheimer's disease neuropathology [2] . One of the earliest observed phenotypes in patients with both Down's syndrome and Alzheimer's disease are abnormally large early endosomal compartments, suggestive of defects in receptor trafficking [3] . Indeed, nerve growth factor transport is impaired in basal forebrain cholinergic neurons in a Down's syndrome mouse model leading to degeneration of these neurons [4] .
Intersectin 1 (ITSN1) is a unique, multidomain scaffold protein encoded by a gene located at 21q22.1-q22.2. ITSN1 mRNA is elevated in Down's syndrome brains [5] . ITSN1 consists of two major splice products, ITSN1short (S) and ITSN1-long (L). Both isoforms possess two Eps15 homology domains, a coiled-coil region, and five Src homology 3 domains; however, ITSN1-L possesses an extended C-terminus encoding a Dbl homology domain, Pleckstrin homology domain, and a C2 domain. The Dbl homology-Pleckstrin homology modules function in concert as a guanine nucleotide exchange factor that specifically activates the Cdc42 GTPase [6] .
Several lines of evidence suggest a link between Down's syndrome neuropathology and ITSN1 (reviewed in reference [6] ). First, ITSN1 acts as an endocytic scaffold regulating the assembly of clathrin-coated pits, and alterations to its expression may contribute to the observed endocytic defects in Down's syndrome. Second, ITSN1 overexpression in model systems results in defective receptor regulation. Third, ITSN1 enhances activation of the c-Jun N-terminal kinase (JNK)-mitogen activated protein kinase pathway. As a specific initiator of the apoptotic response, JNK has been implicated in neurodegeneration [7] . Fourth, whole genome expression analyses reveal that ITSN1 is one of the most highly induced transcripts in Alzheimer's disease brains [8] [9] [10] , consistent with the development of an Alzheimer's disease-like neuropathology in Down's syndrome patients above the age of 40 years [2] . Finally, ITSN1 overexpression enhances neurodegeneration in vivo in a Drosophila model for polyglutamine expansion diseases [11] . These effects involve the JNK pathway and support the notion that ITSN1 and JNK mediate the response of neurons to toxic stress. Together, these data suggest that ITSN1 may contribute to the sequelae of Down's syndrome. ITSN1 expression is widely reported to be elevated in Down's syndrome; however, only a single study has examined this issue, focusing specifically on ITSN1 mRNA levels [5] . Given this paucity of data and lack of information on ITSN1 protein levels in individuals with Down's syndrome, we examined the expression of ITSN1 proteins in cases that are normal and in cases with Down's Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.neuroreport.com).
syndrome. Our study represents the first analysis of ITSN1 protein levels throughout the human lifespan. Finally, we describe the initial characterization of a brainspecific ITSN1-S transgenic mouse which exhibits specific behavioral phenotypes. In conclusion, our findings indicate that ITSN1 proteins are overexpressed in Down's syndrome brains and may contribute to altered behavior in vivo.
Materials and methods

Patients
Frozen tissue blocks from the midfrontal cortex were obtained from a total of 25 individuals (15 male, 10 female) with Down's syndrome ranging in age from 5 months to 62 years of age. A series of 16 control cases (eight male, eight female) ranging in age from 6 months to 67 years were used for comparison. Down's syndrome and young or nondemented aged-control cases were obtained from two sources: (a) the UCI-ADRC Brain Tissue Repository and (b) National Institute of Child Health and Human Development (NICHD) Brain and Tissue Bank for Developmental Disorders.
Tissue isolation ITSN1-S transgenic mice were generated as described in Supplemental digital content 1, http://links.lww.com/WNR/ A147. Mice were killed and brains were removed, placed in ice cold PBS, and brain regions isolated by microdissection. Samples were placed in PLC-lysis buffer [12] supplemented with 1 mM sodium vanadate, 10 mg/ml leupeptin, 1 mM PMSF, 1 mM benzamidine, and 10 mg/ml aprotinin, homogenized, then centrifuged at 14 000 rpm at 41C to remove insoluble debris. Protein concentrations were determined by BCA protein assay (Pierce-Rockford, Illinois, USA). For human tissues, a frozen sample of frontal cortex was homogenized in PLC-lysis buffer with a polytron and then incubated at 41C on a nutator for 20-30 min to enhance solubilization of proteins. Samples were then centrifuged and processed as above.
Antibodies and western blot analysis
The ITSN1 antibody has been previously described [13] . Antibodies to neuron-specific tubulin (Tuj1) and the hemagglutinin epitope (HA.11) are commercially available (Covance-Princeton, New Jersey, USA). Western blot analyses were carried out as described [12] . Differences in the levels of ITSN1-S and ITSN1-L in patient samples were determined by densitometry using ImageJ software (NIH-Bethesda, Maryland, USA) and normalized to the level of tubulin in each sample. The relative expression of ITSN1-S and ITSN1-L was then compared between samples of various ages.
Locomotor activity
A computerized AccuScan 12 Animal Activity Monitoring System (Columbus Instruments, Columbus, Ohio, USA) assisted by VERSAMAX software (AccuScan Instruments, Columbus, Ohio, USA) monitored locomotor activity in mice [14] . Each activity cage consisted of a Perspex box (20 Â 20 Â 20 cm) surrounded by horizontal and vertical infrared sensor beams. The stereotypic time as a measure of the time the animal spent in stereotypic activity such as grooming or head bobbing and the locomotor activity, including horizontal activity and center distance of transgenic mice was recorded between 13 : 00 and 15 : 00 h in the room housing the mice.
Results
ITSN1 mRNA levels are elevated in Down's syndrome [5] . However, little data exists on the expression of ITSN1 proteins in human brains. Therefore, we examined the expression of ITSN1 proteins in frontal cortex samples from normal cases and in cases with Down's syndrome ( Table 1 , Supplemental digital content 2, http://links.lww.com/WNR/A148). The two major ITSN1 isoforms, ITSN1-S and ITSN1-L, were variably expressed in both normal cases and in cases with Down's syndrome (see Fig. 1 , Supplemental digital content 3, http://links.lww.com/WNR/A149). Comparison of ITSN1-S and ITSN1-L levels between normal individuals and patients with Down's syndrome of varying ages indicated that ITSN1-S levels were consistently elevated in cases with Down's syndrome (P = 0.023) ( Fig. 1a ). Although ITSN1-L levels were elevated in Down's syndrome versus control, this difference was not significant (P = 0.12). As patients with Down's syndrome above the age of 40 years invariably develop an early-onset of Alzheimer's disease-like neuropathology [2] , we asked whether ITSN1 levels varied as a function of age as well as genotype (control vs. Down's syndrome) ( Fig. 1b ). For this analysis, cases with Down's syndrome and control cases were grouped as being under the age of 40 years or of 40 years and older, as this is the typical age at which individuals with Down's syndrome have sufficient neuropathology for a diagnosis of Alzheimer's disease. No significant variation was observed in ITSN1 levels with age in control samples although cases with Down's syndrome under the age of 40 years exhibited elevated levels of both ITSN1-S and ITSN1-L (P = 0.021 and 0.035, respectively) ( Fig. 1b) . Interestingly, ITSN1 levels decreased in the older versus younger cases of Down's syndrome. To determine whether there was a correlation between ITSN1 levels and Alzheimer's disease pathology in the cases with Down's syndrome, we stratified samples into control, Down's syndrome, and Down's syndrome with a concurrent diagnosis of Alzheimer's disease ( Fig. 1c ). Both ITSN1-S and ITSN1-L levels are elevated in patients with Down's syndrome (P = 0.01 and 0.026) ( Fig. 1c ). However, ITSN1-S and ITSN1-L levels are reduced in cases with Down's syndrome and Alzheimer's disease compared with Down's syndrome without Alzheimer's disease and these differences are statistically significant (P = 0.026 and 0.015, respectively). Using an independent set of brain samples isolated for cases of similar age but harvested at varying times after death, we did not observe a systematic contribution of the time between tissue harvesting and death (postmortem interval) to the variability in ITSN1-S (Spearman's r = -0.61, P = 0.14) or ITSN1-L (Spearman's r = -0.90, P = 0.85) levels across cases (see Fig. 2 , Supplemental digital content 3).
These results indicate that ITSN1-S and ITSN1-L are upregulated in Down's syndrome brains; however, the contribution of this overexpression to Down's syndrome is unknown. To determine whether ITSN1 overexpression contributes to the sequelae of Down's syndrome, we overexpressed ITSN1-S in the mouse brain. Several observations suggested that overexpression of ITSN1-S may have a greater affect on brain function than ITSN1-L. First, neurons normally express ITSN1-L, but not ITSN1-S [15, 16] . Second, patients with Down's syndrome over 40 years of age develop an Alzheimer's disease-like neuropathology, and ITSN1-S was shown to be specifically overexpressed in neurons from postmortem Alzheimer's disease brain samples [8] [9] [10] .
Finally, overexpression of ITSN1-S increases JNK activation and neurodegeneration [11] .
To determine if brain-specific overexpression of ITSN1-S results in observable phenotypes, we generated mice that overexpress HA-tagged mouse ITSN1-S (HA-ITSN1-S) in the brain by crossing tet-HAITSN1 mice with CaMKII-tTA mice [17] . The CaMKII-tTA drives expression of a transgene from the Tet operon in neurons in forebrain structures with the highest levels in the striatum [17, 18] . Double transgenic CaMKII-tTA:tet-HAITSN1 (hereafter referred to as CaMKII-ITSN1) mice specifically express HA-ITSN1-S in forebrain structures, including the olfactory bulb, cerebral cortex, striatum/septum, hippocampus, and thalamus/hypothalamus with highest levels in the striatum (Fig. 2a) . Relatively low expression was detected in the olfactory bulb, thalamus, and midbrains. In contrast, HA-ITSN1-S was not detected in the cerebellum or in the pons/ medulla. Endogenous ITSN1-S and ITSN1-L are ubiquitously expressed in the brains of single and double transgenic mice, with ITSN1-L as the predominant isoform. However, ITSN1-S expression was elevated relative to ITSN1-L levels in the CaMKII-ITSN1 samples (Fig. 2) . Comparison of total ITSN1 levels (endogenous and HA-ITSN1-S) in the striatums of single (CaMKII and ITSN1) and double (CaMKII-ITSN1) transgenics reveals that the ratio of ITSN1-S-to-ITSN1-L is significantly elevated in double transgenic samples compared with single transgenic samples ( Fig. 2b and c) . These data indicate that HA-ITSN1-S constitutes a significant portion of the total ITSN1 protein in this brain region. Further, the level of ITSN1-S overexpression in the striatum of CaMKII-ITSN1 mice is comparable with the level of ITSN1-S overexpression in the Down's syndrome brain samples, which indicates that this transgenic line is biologically relevant for modeling the effects of ITSN1-S overexpression.
To initially characterize the phenotypic consequences of ITSN1-S overexpression, we measured the locomotor activity of single transgenics and double transgenics in an open-field test. Male CaMKII-ITSN1 mice exhibited an overall reduction in activity compared with the single transgenic control mice (Fig. 3) . Double transgenics exhibited reduced horizontal activity (CaMKII-ITSN1 vs. CaMKII, P = 0.031; CaMKII-ITSN1 vs. ITSN, P = 0.020; Fig. 3a ), exploratory behavior as measured by reduction in center distance (CaMKII-ITSN1 vs. CaM-KII, P = 0.007; CaMKII-ITSN1 vs. ITSN1, P = 0.025; Fig. 3b ), stereotypy time (CaMKII-ITSN1 vs. CaMKII, P = 0.037; CaMKII-ITSN1 vs. ITSN1, P = 0.005; Fig. 3c ), and stereotypy counts (CaMKII-ITSN1 vs. CaMKII, P = 0.029; CaMKII-ITSN1 vs. ITSN1, P = 0.009; Fig. 3d ). Female double transgenics did not exhibit a statistically significant difference in comparison with single transgenics (see Discussion).
Discussion
ITSN1 is a critical regulator of endocytosis, synaptic transmission, and cell signaling [6] . Its localization to HSA21 in the Down's syndrome critical region and elevated expression in mouse models for Down's syndrome suggest that ITSN1 may contribute to the genesis and/or progression of this disorder (reviewed in reference [6] ). Although ITSN1 transcript levels are elevated in the prosencephalon of Down's syndrome, embryos [5] , expression of ITSN1 proteins has not been described. We demonstrate that ITSN1 levels are indeed elevated in frontal cortex of Down's syndrome, with a clear distinction in expression of ITSN1 in younger (aged < 40 years) versus older (aged Z 40 years) cases with Down's syndrome. ITSN1-S and ITSN1-L isoforms were elevated in younger cases with Down's syndrome, but in older cases with Down's syndrome, levels of each isoform were similar to controls. This age stratification of cases corresponds with the appearance of an Alzheimer's disease-like neuropathology in Down's syndrome [2] . This correlation suggests two possibilities: the decrease in ITSN1 levels may result from increased neurodegeneration in older patients with Down's syndrome leading to loss of ITSN1-expressing cells; or ITSN1 overexpression may promote the loss of these neurons. The ratio of ITSN1-S-to-ITSN1-L levels in the striatums was determined from blots in (b) using NIH ImageJ. The differences in ratios were significant (P = 0.022).
To address the biological consequences of ITSN1 overexpression in vivo, we created a novel transgenic mouse model in which ITSN1-S is specifically overexpressed in the forebrain. Although neurons only express ITSN1-L (reviewed in reference [6] ), our mouse model is biologically relevant given the enhanced expression of ITSN1-S in Alzheimer's disease brains [8] [9] [10] and the observed increases in ITSN1-S expression in patients with Down's syndrome. ITSN1-S overexpression resulted in reduced locomotor activity in male CaMKII-ITSN1 mice. Although ITSN1-S overexpression did not result in statistically significant effects in female mice, female mice expressing tTA alone showed reduced center distance (not statistically significant, data not shown). Expression of tTA alone in the Tet system can have a phenotypic effect [19, 20] . However, as the differences in phenotypes between male CaMKII-ITSN1 mice and control animals were statistically significant, we conclude that the reduced activity in these mice is due to brainspecific ITSN1-S overexpression. The highest level of expression of HA-ITSN1 was seen in the striatum, which regulates motor activity. Thus, ITSN1-S may disrupt normal functioning of neurons in the striatum by interfering with endocytic processes in these cells, altering the activity of various signaling pathways, or a combination of both.
Mouse models of Down's syndrome display abnormal behavior [21] . For example, Ts1Cje mice are trisomic for 83 genes including ITSN1, and these mice are hypoactive [21, 22] . However, this mouse model overexpresses many genes and therefore may not be informative with regard to the role of ITSN1 in the abnormal behavioral phenotype. The consequences of elevated ITSN1 levels in patients with Down's syndrome remain unclear. ITSN1 overexpression leads to endocytic defects, enhanced Ras activation, and increased receptor trafficking and degradation (reviewed in reference [6] ). Interestingly, ITSN1-S overexpression increases JNK mitogen activated protein kinase activation leading to enhanced neurodegeneration induced by polyglutamine expanded proteins [11] . These data suggest that ITSN1 overexpression in Down's syndrome may promote neurodegeneration through one or more of these pathways. This hypothesis is consistent with the increase in ITSN1-S transcripts seen in Alzheimer's disease [8] [9] [10] . Thus, it is possible that ITSN1 cooperates with pathways to promote apoptosis of ITSN1overexpressing cells resulting in an age-dependent decrease of ITSN1 in Down's syndrome. However, the role of ITSN1 in Down's syndrome may be more complex. ITSN1 regulates a novel phosphotidylinositol 3-kinase-AKT survival pathway in neurons [12] and may provide a compensatory protective signal in Down's syndrome to counterbalance the negative effects of other overexpressed HSA21 genes as suggested for several HSA21 genes in Down's syndrome [23] . Additional studies using transgenic mice with targeted overexpression of ITSN1-L and overexpression of both ITSN1-S and ITSN1-L in neurons may provide insight into the effects of ITSN1 in Down's syndrome. However, interpretation of such transgenic animals may be complicated given the lack of combinatorial overexpression of HSA21 gene products in single gene transgenics. Indeed, modeling the effects of three Drosophila homologs of HSA21 genes (ITSN1, synaptojanin, and RCAN1) reveals distinct phenotypes in triple versus single or double transgenic flies [24] .
Conclusion
Patients with Down's syndrome express elevated levels of ITSN1-S and ITSN1-L and exhibit a precipitous decrease in ITSN1 protein in aged cases with Down's syndrome coincident with the development of Alzheimer's disease neuropathology. In addition, we have shown that ITSN1-S overexpression in the mouse brain affects behavior.
